{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:29:17Z","timestamp":1747153757713,"version":"3.40.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00259-020-04733-x","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T12:02:32Z","timestamp":1583150552000},"page":"2313-2321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Influence of 18F-FDG PET\/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3345-8750","authenticated-orcid":false,"given":"Susann-Cathrin","family":"Olthof","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6185-4945","authenticated-orcid":false,"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5386-5732","authenticated-orcid":false,"given":"Peter","family":"Martus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-780X","authenticated-orcid":false,"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2668-7325","authenticated-orcid":false,"given":"Konstantin","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-0417","authenticated-orcid":false,"given":"Christian","family":"la Foug\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7761-7592","authenticated-orcid":false,"given":"Brigitte","family":"G\u00fcckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1865-8399","authenticated-orcid":false,"given":"Werner","family":"Vach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4080-5850","authenticated-orcid":false,"given":"Christina","family":"Pfannenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"4733_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/CLEP.S99021","volume":"8","author":"FC Svedman","year":"2016","unstructured":"Svedman FC, et al. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. Clin Epidemiol. 2016;8:109\u201322.","journal-title":"Clin Epidemiol"},{"issue":"3","key":"4733_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3747\/co.24.3432","volume":"24","author":"F Gwadry-Sridhar","year":"2017","unstructured":"Gwadry-Sridhar F, et al. Resource utilization and costs of managing patients with advanced melanoma: a Canadian population-based study. Curr Oncol. 2017;24(3):168\u201375.","journal-title":"Curr Oncol"},{"issue":"3","key":"4733_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ad.2016.09.010","volume":"108","author":"P Serra-Arbeloa","year":"2017","unstructured":"Serra-Arbeloa P, et al. Cost of cutaneous melanoma by tumor stage: a descriptive analysis. Actas Dermosifiliogr. 2017;108(3):229\u201336.","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"4733_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ejca.2006.11.014","volume":"43","author":"C Pfannenberg","year":"2007","unstructured":"Pfannenberg C, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer. 2007;43(3):557\u201364.","journal-title":"Eur J Cancer"},{"issue":"2","key":"4733_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00117-014-2762-z","volume":"55","author":"C Pfannenberg","year":"2015","unstructured":"Pfannenberg C, Schwenzer N. Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI. Radiologe. 2015;55(2):120\u20136.","journal-title":"Radiologe"},{"issue":"4","key":"4733_CR6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00259-015-3217-0","volume":"43","author":"H Petersen","year":"2016","unstructured":"Petersen H, et al. FDG PET\/CT in cancer: comparison of actual use with literature-based recommendations. Eur J Nucl Med Mol Imaging. 2016;43(4):695\u2013706.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9315","key":"4733_CR7","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/S0140-6736(02)08352-6","volume":"359","author":"H van Tinteren","year":"2002","unstructured":"van Tinteren H, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359(9315):1388\u201393.","journal-title":"Lancet"},{"issue":"4","key":"4733_CR8","first-page":"435","volume":"11","author":"T Merlin","year":"2014","unstructured":"Merlin T. The use of the \u2018linked evidence approach\u2019 to guide policy on the reimbursement of personalized medicines. Perinat Med. 2014;11(4):435\u201348.","journal-title":"Perinat Med"},{"key":"4733_CR9","doi-asserted-by":"crossref","unstructured":"Forschner A, et al. Impact of 18F-FDG-PET\/CT on surgical management in patients with advanced melanoma: an outcome based analysis. Eur J Nucl Med Mol Imaging. 2017;44(8):1312\u20131318.","DOI":"10.1007\/s00259-017-3674-8"},{"issue":"1","key":"4733_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00259-018-4156-3","volume":"46","author":"C Pfannenberg","year":"2019","unstructured":"Pfannenberg C, et al. Practice-based evidence for the clinical benefit of PET\/CT-results of the first oncologic PET\/CT registry in Germany. Eur J Nucl Med Mol Imaging. 2019;46(1):54\u201364.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"4733_CR11","first-page":"17","volume":"4","author":"M Danielsen","year":"2013","unstructured":"Danielsen M, et al. Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. Am J Nucl Med Mol Imaging. 2013;4(1):17\u201328.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"5","key":"4733_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3413\/Nukmed-0584-13-05","volume":"52","author":"HA Wieder","year":"2013","unstructured":"Wieder HA, et al. 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma. Nuklearmedizin. 2013;52(5):198\u2013203.","journal-title":"Nuklearmedizin"},{"issue":"6","key":"4733_CR13","first-page":"255","volume":"7","author":"PH Vensby","year":"2017","unstructured":"Vensby PH, et al. The value of FDG PET\/CT for follow-up of patients with melanoma: a retrospective analysis. Am J Nucl Med Mol Imaging. 2017;7(6):255\u201362.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"26","key":"4733_CR14","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1200\/JCO.2009.26.9357","volume":"28","author":"SK Lutgendorf","year":"2010","unstructured":"Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol. 2010;28(26):4094\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4733_CR15","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/SLA.0000000000000233","volume":"259","author":"NM Rueth","year":"2014","unstructured":"Rueth NM, et al. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014;259(6):1215\u201322.","journal-title":"Ann Surg"},{"key":"4733_CR16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.14694\/EDBK_174934","volume":"37","author":"M Yushak","year":"2017","unstructured":"Yushak M, et al. Systemic therapy options for patients with unresectable melanoma. Am Soc Clin Oncol Educ Book. 2017;37:661\u201372.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"4733_CR17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00432-016-2309-y","volume":"143","author":"A Forschner","year":"2017","unstructured":"Forschner A, et al. Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). J Cancer Res Clin Oncol. 2017;143(3):533\u201340.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"4733_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","volume":"34","author":"GV Long","year":"2016","unstructured":"Long GV, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol. 2016;34(8):871\u20138.","journal-title":"J Clin Oncol"},{"key":"4733_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1745-6215-13-137","volume":"13","author":"M Rodger","year":"2012","unstructured":"Rodger M, Ramsay T, Fergusson D. Diagnostic randomized controlled trials: the final frontier. Trials. 2012;13:137.","journal-title":"Trials"},{"issue":"2","key":"4733_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/0272989X9101100203","volume":"11","author":"DG Fryback","year":"1991","unstructured":"Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Mak. 1991;11(2):88\u201394.","journal-title":"Med Decis Mak"},{"issue":"3","key":"4733_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1017\/S0266462313000287","volume":"29","author":"T Merlin","year":"2013","unstructured":"Merlin T, et al. The \u201clinked evidence approach\u201d to assess medical tests: a critical analysis. Int J Technol Assess Health Care. 2013;29(3):343\u201350.","journal-title":"Int J Technol Assess Health Care"},{"key":"4733_CR22","unstructured":"Albano D, et al. Clinical and prognostic value of 18F-FDG-PET\/CT in the restaging process of recurrent cutaneous melanoma. Curr Radiopharm. 2019;26(13):4610\u20134618."},{"issue":"4","key":"4733_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jso.20079","volume":"86","author":"U Leiter","year":"2004","unstructured":"Leiter U, et al. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86(4):172\u20138.","journal-title":"J Surg Oncol"},{"issue":"13","key":"4733_CR24","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1245\/s10434-019-07487-5","volume":"26","author":"DW Nelson","year":"2019","unstructured":"Nelson DW, et al. Impact of effective systemic therapy on metastasectomy in stage IV melanoma: a matched-pair analysis. Ann Surg Oncol. 2019;26(13):4610\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"33","key":"4733_CR25","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1200\/JCO.2008.18.3996","volume":"26","author":"MN Levine","year":"2008","unstructured":"Levine MN, Julian JA. Registries that show efficacy: good, but not good enough. J Clin Oncol. 2008;26(33):5316\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4733_CR26","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2967\/jnumed.107.043687","volume":"48","author":"BE Hillner","year":"2007","unstructured":"Hillner BE, et al. The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med. 2007;48(11):1901\u20138.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04733-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-020-04733-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04733-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:34:04Z","timestamp":1614645244000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-020-04733-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["4733"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-04733-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"type":"print","value":"1619-7070"},{"type":"electronic","value":"1619-7089"}],"subject":[],"published":{"date-parts":[[2020,3,2]]},"assertion":[{"value":"17 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was reviewed and approved by the institutional review board and the local ethics committee (reference number 064\/2013BO1).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}